MX2017016347A - Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal. - Google Patents
Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.Info
- Publication number
- MX2017016347A MX2017016347A MX2017016347A MX2017016347A MX2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A MX 2017016347 A MX2017016347 A MX 2017016347A
- Authority
- MX
- Mexico
- Prior art keywords
- sinus node
- cardiac myosin
- combination therapy
- current inhibitor
- myosin activator
- Prior art date
Links
- 102000013602 Cardiac Myosins Human genes 0.000 title abstract 3
- 108010051609 Cardiac Myosins Proteins 0.000 title abstract 3
- 229940098712 Myosin activator Drugs 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 210000001013 sinoatrial node Anatomy 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- RFUBTTPMWSKEIW-UHFFFAOYSA-N omecamtiv mecarbil Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1F RFUBTTPMWSKEIW-UHFFFAOYSA-N 0.000 abstract 1
- 229950001617 omecamtiv mecarbil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen en la presente terapias de combinación para el tratamiento de insuficiencia cardíaca mediante el uso del activador de miosina cardíaca, tal como omecamtiv mecarbil, y un inhibidor de corriente If del nodo sinusal. Se describen adicionalmente en la presente composiciones que comprenden un activador de miosina cardíaca y un inhibidor de corriente If del nodo sinusal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185306P | 2015-06-26 | 2015-06-26 | |
| PCT/US2016/039198 WO2016210240A1 (en) | 2015-06-26 | 2016-06-24 | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017016347A true MX2017016347A (es) | 2018-08-15 |
| MX379899B MX379899B (es) | 2025-03-11 |
Family
ID=56409184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016347A MX379899B (es) | 2015-06-26 | 2016-06-24 | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10543215B2 (es) |
| EP (1) | EP3313444B1 (es) |
| JP (1) | JP6858716B2 (es) |
| AU (1) | AU2016282985B2 (es) |
| CA (1) | CA2988796A1 (es) |
| MX (1) | MX379899B (es) |
| WO (1) | WO2016210240A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009726A2 (en) | 2004-06-17 | 2006-01-26 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| AP2015008789A0 (en) | 2013-03-14 | 2015-10-31 | Cytokinetics Inc | Heterocyclic compounds and their uses |
| MD3645518T2 (ro) | 2017-06-30 | 2021-11-30 | Amgen Inc | Sinteză de mercabil omecamtiv |
| CN110996953A (zh) * | 2017-06-30 | 2020-04-10 | 安进公司 | 用心脏肌小节激活剂治疗心力衰竭的方法 |
| CA3075669A1 (en) | 2017-09-13 | 2019-03-21 | Amgen Inc. | Bisamide sarcomere activating compounds and uses thereof |
| LT3594199T (lt) | 2018-07-09 | 2020-11-10 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Kristalinis 2-fluor-3-nitroluenas ir jo paruošimo būdas |
| CA3108800A1 (en) | 2018-08-17 | 2020-02-20 | Amgen Inc. | Salts and crystal forms of omecamtiv mecarbil |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| EP4243825B1 (en) | 2020-11-12 | 2025-11-12 | Amgen Inc. | Omecamtiv mecarbil for the treatment of heart failure in selected patient groups |
| WO2022192414A2 (en) | 2021-03-10 | 2022-09-15 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681862B1 (fr) | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
| WO2006009726A2 (en) | 2004-06-17 | 2006-01-26 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| FR3001151B1 (fr) * | 2013-01-21 | 2016-04-08 | Pf Medicament | Association d'un bloqueur de courant sodique lent et d'un inhibiteur du courant if sinusal et les compositions pharmarceutiques la contenant |
| AP2015008789A0 (en) * | 2013-03-14 | 2015-10-31 | Cytokinetics Inc | Heterocyclic compounds and their uses |
-
2016
- 2016-06-24 US US15/578,305 patent/US10543215B2/en active Active
- 2016-06-24 JP JP2017566330A patent/JP6858716B2/ja active Active
- 2016-06-24 EP EP16738288.6A patent/EP3313444B1/en active Active
- 2016-06-24 MX MX2017016347A patent/MX379899B/es unknown
- 2016-06-24 WO PCT/US2016/039198 patent/WO2016210240A1/en not_active Ceased
- 2016-06-24 CA CA2988796A patent/CA2988796A1/en active Pending
- 2016-06-24 AU AU2016282985A patent/AU2016282985B2/en active Active
-
2019
- 2019-12-04 US US16/702,989 patent/US20200108076A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6858716B2 (ja) | 2021-04-14 |
| AU2016282985A1 (en) | 2017-12-14 |
| AU2016282985B2 (en) | 2021-07-29 |
| EP3313444B1 (en) | 2020-10-21 |
| US20200108076A1 (en) | 2020-04-09 |
| US20180140611A1 (en) | 2018-05-24 |
| CA2988796A1 (en) | 2016-12-29 |
| MX379899B (es) | 2025-03-11 |
| JP2018518501A (ja) | 2018-07-12 |
| WO2016210240A1 (en) | 2016-12-29 |
| US10543215B2 (en) | 2020-01-28 |
| EP3313444A1 (en) | 2018-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017016347A (es) | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal. | |
| DOP2022000172A (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| UY36143A (es) | Derivados de pirazolo-pirimidina novedosos | |
| GT201500348A (es) | Compuestos de pirimidinodiona contra estados cardíacos | |
| ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| CO2019005059A2 (es) | Inhibidores de magl | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| CO2019005038A2 (es) | Inhibidores de magl | |
| CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| CR20180228A (es) | Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma | |
| CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CL2018000742A1 (es) | Uso de trientina para el suministro de cobre a un tejido isquémico | |
| BR112018000217A2 (pt) | sistemas de distribuição de nanopartículas aperfeiçoados | |
| MX2016010524A (es) | Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico. | |
| MX2017008373A (es) | Compuestos, composiciones y metodos. | |
| MX2018003289A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO. | |
| BR112017012931A2 (pt) | métodos para redução de agregação plaquetária e tratamento de doença cardiovascular e outros distúrbios médicos |